Virtus Biotech Clinical Trials ETF
18 hedge funds and large institutions have $8.24M invested in Virtus Biotech Clinical Trials ETF in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 17 → 18 (+1)
6% less capital inflows, than outflows
Capital inflows: $1.08M | Capital outflows: $1.15M
2.01% less ownership
Funds ownership: 36.3% → 34.29% (-2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Advisory Services Network
Atlanta,
Georgia
|
+$443K |
| 2 |
Private Advisor Group
Morristown,
New Jersey
|
+$206K |
| 3 |
Virtu KCG Holdings
New York
|
+$147K |
| 4 |
SG Americas Securities
New York
|
+$94.2K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$88.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$747K |
| 2 |
LPL Financial
San Diego,
California
|
-$329K |
| 3 |
Goldman Sachs
New York
|
-$51.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$20K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$5K |
BBC Hedge Fund Activity: Q2 2017 in Review
18 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2017, worth a combined $8.24M — up 3.1% from $7.99M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBC positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Advisory Services Network, adding an estimated $443K. The largest seller was Jane Street, exiting entirely with an estimated $747K sold.
- 18 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2017, up from 17 in Q1 2017.
- Funds reported $8.24M of Virtus Biotech Clinical Trials ETF stock for Q2 2017, up 3.1% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2017 and 2 closed out, a net change of +1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2017 was Advisory Services Network, an estimated $443K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2017 was Jane Street, an estimated $747K sold.
Based on aggregated 13F filings for Q2 2017.